1. Home
  2. SHOT vs ANTX Comparison

SHOT vs ANTX Comparison

Compare SHOT & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SHOT
  • ANTX
  • Stock Information
  • Founded
  • SHOT 2018
  • ANTX 2017
  • Country
  • SHOT United States
  • ANTX United States
  • Employees
  • SHOT N/A
  • ANTX N/A
  • Industry
  • SHOT Biotechnology: Pharmaceutical Preparations
  • ANTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SHOT Health Care
  • ANTX Health Care
  • Exchange
  • SHOT Nasdaq
  • ANTX Nasdaq
  • Market Cap
  • SHOT 44.2M
  • ANTX 37.6M
  • IPO Year
  • SHOT 2020
  • ANTX 2022
  • Fundamental
  • Price
  • SHOT $0.54
  • ANTX $1.27
  • Analyst Decision
  • SHOT
  • ANTX Hold
  • Analyst Count
  • SHOT 0
  • ANTX 5
  • Target Price
  • SHOT N/A
  • ANTX $3.50
  • AVG Volume (30 Days)
  • SHOT 917.5K
  • ANTX 143.7K
  • Earning Date
  • SHOT 11-14-2024
  • ANTX 11-13-2024
  • Dividend Yield
  • SHOT N/A
  • ANTX N/A
  • EPS Growth
  • SHOT N/A
  • ANTX N/A
  • EPS
  • SHOT N/A
  • ANTX N/A
  • Revenue
  • SHOT $652,495.00
  • ANTX N/A
  • Revenue This Year
  • SHOT N/A
  • ANTX N/A
  • Revenue Next Year
  • SHOT N/A
  • ANTX N/A
  • P/E Ratio
  • SHOT N/A
  • ANTX N/A
  • Revenue Growth
  • SHOT 68.01
  • ANTX N/A
  • 52 Week Low
  • SHOT $0.51
  • ANTX $0.87
  • 52 Week High
  • SHOT $4.05
  • ANTX $21.40
  • Technical
  • Relative Strength Index (RSI)
  • SHOT 27.44
  • ANTX 44.51
  • Support Level
  • SHOT $0.69
  • ANTX $1.34
  • Resistance Level
  • SHOT $0.60
  • ANTX $1.28
  • Average True Range (ATR)
  • SHOT 0.07
  • ANTX 0.06
  • MACD
  • SHOT -0.01
  • ANTX -0.02
  • Stochastic Oscillator
  • SHOT 8.33
  • ANTX 21.74

About SHOT Safety Shot Inc.

Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.

About ANTX AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Share on Social Networks: